作者:Andrew D. Napper、Jeffrey Hixon、Thomas McDonagh、Kenneth Keavey、Jean-Francois Pons、Jonathan Barker、Wei Tsung Yau、Patricia Amouzegh、Adam Flegg、Estelle Hamelin、Russell J. Thomas、Michael Kates、Stephen Jones、Manuel A. Navia、Jeffrey O. Saunders、Peter S. DiStefano、Rory Curtis
DOI:10.1021/jm050522v
日期:2005.12.1
against the human sirtuin SIRT1 led to the discovery of a series of indoles as potent inhibitors that are selective for SIRT1 over other deacetylases and NAD-processing enzymes. The most potent compounds described herein inhibit SIRT1 with IC50 values of 60-100 nM, representing a 500-fold improvement over previously reported SIRT inhibitors. Preparation of enantiomerically pure indole derivatives allowed
针对人类sirtuin SIRT1的高通量筛选导致发现了一系列吲哚,它们是对SIRT1选择性强于其他脱乙酰基酶和NAD加工酶的有效抑制剂。本文描述的最有效的化合物以60-100 nM的IC50值抑制SIRT1,这比以前报道的SIRT抑制剂提高了500倍。对映体纯的吲哚衍生物的制备使其能够在体外和体内表征。动力学分析表明,这些抑制剂在烟酰胺从酶中释放后结合,并阻止了脱乙酰肽和O-乙酰-ADP-核糖的释放,O-乙酰-ADP-核糖是酶催化的脱乙酰产物。这些SIRT1抑制剂是低分子量的,细胞可渗透的,口服可生物利用的和代谢稳定的。